BAXTER INTERNATIONAL INC (BAX) Fundamental Analysis & Valuation

NYSE:BAX • US0718131099

Current stock price

18.84 USD
+0.13 (+0.69%)
At close:
19 USD
+0.16 (+0.85%)
Pre-Market:

This BAX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. BAX Profitability Analysis

1.1 Basic Checks

  • In the past year BAX was profitable.
  • BAX had a positive operating cash flow in the past year.
  • In multiple years BAX reported negative net income over the last 5 years.
  • In the past 5 years BAX always reported a positive cash flow from operatings.
BAX Yearly Net Income VS EBIT VS OCF VS FCFBAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -4.77%, BAX is in the better half of the industry, outperforming 68.45% of the companies in the same industry.
  • The Return On Equity of BAX (-15.61%) is better than 63.10% of its industry peers.
  • BAX has a Return On Invested Capital of 1.97%. This is in the better half of the industry: BAX outperforms 69.52% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BAX is significantly below the industry average of 9.12%.
Industry RankSector Rank
ROA -4.77%
ROE -15.61%
ROIC 1.97%
ROA(3y)0.7%
ROA(5y)-0.53%
ROE(3y)2.23%
ROE(5y)-4.18%
ROIC(3y)3.01%
ROIC(5y)3.68%
BAX Yearly ROA, ROE, ROICBAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

1.3 Margins

  • Looking at the Operating Margin, with a value of 3.78%, BAX is in the better half of the industry, outperforming 70.05% of the companies in the same industry.
  • BAX's Operating Margin has declined in the last couple of years.
  • BAX has a worse Gross Margin (30.68%) than 73.80% of its industry peers.
  • In the last couple of years the Gross Margin of BAX has declined.
Industry RankSector Rank
OM 3.78%
PM (TTM) N/A
GM 30.68%
OM growth 3Y-22.24%
OM growth 5Y-24.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.08%
GM growth 5Y-5.03%
BAX Yearly Profit, Operating, Gross MarginsBAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. BAX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BAX is destroying value.
  • The number of shares outstanding for BAX has been increased compared to 1 year ago.
  • BAX has more shares outstanding than it did 5 years ago.
  • BAX has a better debt/assets ratio than last year.
BAX Yearly Shares OutstandingBAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
BAX Yearly Total Debt VS Total AssetsBAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 2.24 indicates that BAX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • BAX has a Altman-Z score of 2.24. This is in the better half of the industry: BAX outperforms 62.03% of its industry peers.
  • BAX has a debt to FCF ratio of 28.54. This is a negative value and a sign of low solvency as BAX would need 28.54 years to pay back of all of its debts.
  • BAX's Debt to FCF ratio of 28.54 is fine compared to the rest of the industry. BAX outperforms 66.84% of its industry peers.
  • BAX has a Debt/Equity ratio of 1.55. This is a high value indicating a heavy dependency on external financing.
  • BAX's Debt to Equity ratio of 1.55 is on the low side compared to the rest of the industry. BAX is outperformed by 80.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF 28.54
Altman-Z 2.24
ROIC/WACC0.37
WACC5.35%
BAX Yearly LT Debt VS Equity VS FCFBAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.31 indicates that BAX has no problem at all paying its short term obligations.
  • BAX has a Current ratio (2.31) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.56 indicates that BAX should not have too much problems paying its short term obligations.
  • The Quick ratio of BAX (1.56) is worse than 60.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 1.56
BAX Yearly Current Assets VS Current LiabilitesBAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BAX Growth Analysis

3.1 Past

  • BAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.24%.
  • Measured over the past years, BAX shows a decrease in Earnings Per Share. The EPS has been decreasing by -5.98% on average per year.
  • Looking at the last year, BAX shows a very negative growth in Revenue. The Revenue has decreased by -12.54% in the last year.
  • BAX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.75% yearly.
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
Revenue 1Y (TTM)-12.54%
Revenue growth 3Y-9.39%
Revenue growth 5Y-0.75%
Sales Q2Q%8.03%

3.2 Future

  • Based on estimates for the next years, BAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.15% on average per year.
  • BAX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.51% yearly.
EPS Next Y-14.55%
EPS Next 2Y-4.68%
EPS Next 3Y0.24%
EPS Next 5Y9.15%
Revenue Next Year2.42%
Revenue Next 2Y2.32%
Revenue Next 3Y2.41%
Revenue Next 5Y2.51%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BAX Yearly Revenue VS EstimatesBAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5B 10B 15B
BAX Yearly EPS VS EstimatesBAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. BAX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 8.30, the valuation of BAX can be described as reasonable.
  • Based on the Price/Earnings ratio, BAX is valued cheaper than 95.19% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of BAX to the average of the S&P500 Index (27.95), we can say BAX is valued rather cheaply.
  • The Price/Forward Earnings ratio is 9.71, which indicates a very decent valuation of BAX.
  • Based on the Price/Forward Earnings ratio, BAX is valued cheaply inside the industry as 95.72% of the companies are valued more expensively.
  • BAX is valuated cheaply when we compare the Price/Forward Earnings ratio to 38.68, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 8.3
Fwd PE 9.71
BAX Price Earnings VS Forward Price EarningsBAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BAX is valued cheaper than 87.70% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BAX is valued a bit cheaper than the industry average as 78.07% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 29.3
EV/EBITDA 12.26
BAX Per share dataBAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.68%
EPS Next 3Y0.24%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. BAX Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.22%, BAX is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.25, BAX pays a better dividend. On top of this BAX pays more dividend than 89.84% of the companies listed in the same industry.
  • With a Dividend Yield of 0.22, BAX pays less dividend than the S&P500 average, which is at 1.81.
Industry RankSector Rank
Dividend Yield 0.22%

5.2 History

  • The dividend of BAX decreases each year by -6.21%.
  • BAX has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-6.21%
Div Incr Years0
Div Non Decr Years0
BAX Yearly Dividends per shareBAX Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • The earnings of BAX are negative and hence is the payout ratio. BAX will probably not be able to sustain this dividend level.
DP-36.36%
EPS Next 2Y-4.68%
EPS Next 3Y0.24%
BAX Yearly Income VS Free CF VS DividendBAX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B -2B 4B

More info and screens

Find the best dividend stocksShow peers with best dividend

BAX Fundamentals: All Metrics, Ratios and Statistics

BAXTER INTERNATIONAL INC

NYSE:BAX (4/20/2026, 8:04:00 PM)

Premarket: 19 +0.16 (+0.85%)

18.84

+0.13 (+0.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-30
Inst Owners109.33%
Inst Owner Change-2.9%
Ins Owners0.18%
Ins Owner Change7.47%
Market Cap9.73B
Revenue(TTM)11.24B
Net Income(TTM)-957.00M
Analysts64.55
Price Target21.88 (16.14%)
Short Float %7.87%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield 0.22%
Yearly Dividend0.68
Dividend Growth(5Y)-6.21%
DP-36.36%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-27
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.28%
Min EPS beat(2)-18.72%
Max EPS beat(2)14.16%
EPS beat(4)2
Avg EPS beat(4)0.98%
Min EPS beat(4)-18.72%
Max EPS beat(4)14.16%
EPS beat(8)6
Avg EPS beat(8)3.02%
EPS beat(12)9
Avg EPS beat(12)2.81%
EPS beat(16)10
Avg EPS beat(16)2.49%
Revenue beat(2)1
Avg Revenue beat(2)0.95%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)4.28%
Revenue beat(4)2
Avg Revenue beat(4)0.23%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)4.28%
Revenue beat(8)5
Avg Revenue beat(8)0.31%
Revenue beat(12)7
Avg Revenue beat(12)0.01%
Revenue beat(16)7
Avg Revenue beat(16)-1.2%
PT rev (1m)-1.48%
PT rev (3m)-7.82%
EPS NQ rev (1m)1.52%
EPS NQ rev (3m)-35.14%
EPS NY rev (1m)0.1%
EPS NY rev (3m)-14.91%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)-0.86%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.45%
Valuation
Industry RankSector Rank
PE 8.3
Fwd PE 9.71
P/S 0.87
P/FCF 29.3
P/OCF 11.51
P/B 1.59
P/tB N/A
EV/EBITDA 12.26
EPS(TTM)2.27
EY12.05%
EPS(NY)1.94
Fwd EY10.3%
FCF(TTM)0.64
FCFY3.41%
OCF(TTM)1.64
OCFY8.69%
SpS21.78
BVpS11.87
TBVpS-6.14
PEG (NY)N/A
PEG (5Y)N/A
Graham Number24.6246 (30.7%)
Profitability
Industry RankSector Rank
ROA -4.77%
ROE -15.61%
ROCE 2.49%
ROIC 1.97%
ROICexc 2.22%
ROICexgc 5.77%
OM 3.78%
PM (TTM) N/A
GM 30.68%
FCFM 2.95%
ROA(3y)0.7%
ROA(5y)-0.53%
ROE(3y)2.23%
ROE(5y)-4.18%
ROIC(3y)3.01%
ROIC(5y)3.68%
ROICexc(3y)3.41%
ROICexc(5y)4.11%
ROICexgc(3y)9.09%
ROICexgc(5y)11.24%
ROCE(3y)3.97%
ROCE(5y)4.78%
ROICexgc growth 3Y-20.11%
ROICexgc growth 5Y-19.9%
ROICexc growth 3Y-20.01%
ROICexc growth 5Y-27.24%
OM growth 3Y-22.24%
OM growth 5Y-24.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.08%
GM growth 5Y-5.03%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 1.55
Debt/FCF 28.54
Debt/EBITDA 6.74
Cap/Depr 52.29%
Cap/Sales 4.56%
Interest Coverage 1.4
Cash Conversion 60.1%
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 1.56
Altman-Z 2.24
F-Score4
WACC5.35%
ROIC/WACC0.37
Cap/Depr(3y)50.61%
Cap/Depr(5y)56.74%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
EPS Next Y-14.55%
EPS Next 2Y-4.68%
EPS Next 3Y0.24%
EPS Next 5Y9.15%
Revenue 1Y (TTM)-12.54%
Revenue growth 3Y-9.39%
Revenue growth 5Y-0.75%
Sales Q2Q%8.03%
Revenue Next Year2.42%
Revenue Next 2Y2.32%
Revenue Next 3Y2.41%
Revenue Next 5Y2.51%
EBIT growth 1Y-55.07%
EBIT growth 3Y-29.54%
EBIT growth 5Y-24.96%
EBIT Next Year37.67%
EBIT Next 3Y12.11%
EBIT Next 5Y17.39%
FCF growth 1Y-42.06%
FCF growth 3Y-14.54%
FCF growth 5Y-22.12%
OCF growth 1Y-17.08%
OCF growth 3Y-11.3%
OCF growth 5Y-14.67%

BAXTER INTERNATIONAL INC / BAX Fundamental Analysis FAQ

What is the fundamental rating for BAX stock?

ChartMill assigns a fundamental rating of 4 / 10 to BAX.


Can you provide the valuation status for BAXTER INTERNATIONAL INC?

ChartMill assigns a valuation rating of 6 / 10 to BAXTER INTERNATIONAL INC (BAX). This can be considered as Fairly Valued.


How profitable is BAXTER INTERNATIONAL INC (BAX) stock?

BAXTER INTERNATIONAL INC (BAX) has a profitability rating of 4 / 10.


What is the valuation of BAXTER INTERNATIONAL INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BAXTER INTERNATIONAL INC (BAX) is 8.3 and the Price/Book (PB) ratio is 1.59.


How financially healthy is BAXTER INTERNATIONAL INC?

The financial health rating of BAXTER INTERNATIONAL INC (BAX) is 4 / 10.